TY  - JOUR
AU  - Perez-Belmonte, Luis M
AU  - Sanz-Canovas, Jaime
AU  - Garcia-de-Lucas, Maria D
AU  - Ricci, Michele
AU  - Aviles-Bueno, Beatriz
AU  - Cobos-Palacios, Lidia
AU  - Perez-Velasco, Miguel A
AU  - Lopez-Sampalo, Almudena
AU  - Bernal-Lopez, M Rosa
AU  - Jansen-Chaparro, Sergio
AU  - Miramontes-Gonzalez, Jose P
AU  - Gomez-Huelgas, Ricardo
PY  - 2022
DO  - 10.3389/fendo.2022.851035
SN  - 1664-2392
UR  - http://hdl.handle.net/10668/20560
T2  - Frontiers in endocrinology
AB  - The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with...
LA  - en
PB  - Frontiers Research Foundation
KW  - Health status
KW  - Heart failure
KW  - Obesity
KW  - Semaglutide
KW  - Type 2 diabetes
KW  - Diabetes Mellitus, Type 2
KW  - Glucagon-Like Peptide-1 Receptor
KW  - Glucagon-Like Peptides
KW  - Heart Failure
KW  - Humans
KW  - Obesity
KW  - Retrospective Studies
TI  - Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
TY  - research article
VL  - 13
ER  -